Navigation Links
Sangamo BioSciences Announces Presentation of Phase 1 ZFP,Therapeutic Data at American Diabetes Association Meeting

reversible.

"We are pleased that our SB-509 diabetic neuropathy program Phase 1 update was selected for an oral presentation at the most significant US diabetes meeting of the year," said Edward Lanphier, Sangamo's president and CEO. "We believe that SB-509 represents a new therapeutic approach for diabetic neuropathy, designed to directly protect and possibly restore nerve function, in contrast to the current standard of care designed to address the pain associated with this condition. We expect to provide an additional update on the progress of this trial later in the year. We are encouraged by the data so far and are swiftly moving forward to the next stage of clinical development with our two ongoing Phase 2 clinical trials."

About the SB-509 Clinical Program

SB-509 is an injectable formulation of plasmid DNA that encodes a ZFP TF, designed to upregulate the VEGF-A gene.

Phase 1

Phase 1b study to assess the safety and clinical effects of a single administration of SB-509 to subjects is ongoing. Subjects were randomized and administered either SB-509 or placebo in both legs by intramuscular injection. Two dose levels of SB-509 have been tested. At the first dose level, three subjects were administered placebo and three subjects were treated with a total of 30 mg of SB-509, 15 mg per leg. Accrual of these subjects is complete. A further twenty-two subjects have been treated at the second dose level with either placebo or a total dose of 60 mg of SB-509, administered as 30 mg per leg. Subjects in this Phase 1b study will be monitored for both the safety and tolerability of SB-509 treatment as well as evaluation of pain and clinical effects on lower limb diabetic neuropathy at one, two, three and six months post-treatment.

Phase 2

Sangamo has two ongoing Phase 2 studies in diabetics with sensory/motor neuropathy:

Phase 2 study of SB-509 for mild to moderate DN

The clinical trial is a double-blind, placeb
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data From Nerve Regeneration Program at American Society for Neural Therapy and Repair Meeting
2. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
3. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
4. IR BioSciences Announces Promising Data from Study of Its Compound Homspera
5. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
6. ImmuneRegen BioSciences Announces Promising Data on Homspera Suggesting Potential as a Co-Therapeutic Agent
7. Study in Cell by Magen BioSciences Co-Founder David E. Fisher Identifies New Roles in Skin Cancer Prevention for Key Tumor Suppressor Protein
8. IR BioSciences Announces Data Demonstrating Radilex Stimulation of Stem Cells Results in Hematopoietic Recovery Following Lethal Irradiation
9. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
10. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
Post Your Comments:
(Date:1/23/2015)... , Jan. 23, 2015 More than a third of ... of those with private insurance, filled a prescription for an ... report in this week,s Morbidity and Mortality Weekly Report (MMWR). ... providers to treat moderate to severe pain.  They are also ...
(Date:1/23/2015)...  HyGreen, Inc., a leader in hand hygiene monitoring, today ... a subsidiary of Ascendis Health Limited, in ... hundreds of millions of patients around the world are ... from patient to patient via the unwashed hands of ...
(Date:1/23/2015)... Cord Blood America, Inc. ( www.cordblood-america.com ) (OTC Bulletin Board: ... Preliminary Proxy Statement, Schedule 14A, with the U.S. Securities & ... for shareholders detailing why a "YES" vote to increase the ... As we reflect upon the 2014 fiscal year ...
Breaking Medicine Technology:Opioid painkillers widely prescribed among reproductive age women 2Opioid painkillers widely prescribed among reproductive age women 3HyGreen Partners with RCA Medical in Johannesburg, South Africa 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4
... Reportlinker.com announces that a new market research ... Innovations in Wound Care Devices and ... Introduction Wound ... range of sizes, shapes, stages, and types ...
... 2012 /PRNewswire-iReach/ -- Global Information, Inc. (GII) is ... Devices - Global Pipeline Analysis, Competitive Landscape and Market Forecasts ... The Insulin Delivery Devices Market is ... $11 Billion by 2017 GlobalData estimated ...
Cached Medicine Technology:Innovations in Wound Care Devices and Dressings 2Innovations in Wound Care Devices and Dressings 3Innovations in Wound Care Devices and Dressings 4Insulin Delivery Devices - Increasing Prevalence of Diabetes to Drive the Market 2Insulin Delivery Devices - Increasing Prevalence of Diabetes to Drive the Market 3Insulin Delivery Devices - Increasing Prevalence of Diabetes to Drive the Market 4
(Date:1/23/2015)... Phoenix, AZ (PRWEB) January 23, 2015 Hastings ... personal injury matters, reports a record number of legal representation ... Statistically speaking, there has been a steady rise in the ... at work and at home throughout the Valley. With that ... their accident be reviewed by an experienced law firm. Hastings ...
(Date:1/22/2015)... January 22, 2015 Liberty University has received ... program from the Council for Accreditation of Counseling ... of Liberty’s Center for Counseling & Family Studies , ... of the university’s new School of Behavioral Sciences. Prior to ...
(Date:1/22/2015)... Woodloch Pines, an all-inclusive family resort ... as the number one best large hotel for families in ... for their annual Travelers’ Choice Awards. , TripAdvisor represents ... is home to millions of unbiased and honest traveler reviews. ...
(Date:1/22/2015)... is a seasoned and trusted leader who consistently delivers trendy ... have it lead the wedding dress industry into the future. ... for the global market. , “The CEO of VogueQueen is ... on continuing the goal of operational excellence and giving back ...
(Date:1/22/2015)... 2015 Blue Cross and Blue Shield of ... what it means to “Live Fearless.” , The ... share their stories about how they or someone they know ... by living in the moment. By telling these types of ...
Breaking Medicine News(10 mins):Health News:Hastings and Hastings Reports a Record Number of Client Review Requests for Slip and Fall Accidents in 2014 2Health News:Liberty University's Resident Master’s Counseling Program Receives CACREP Accreditation 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 3Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2
... 26 (HealthDay News) -- If you,re told that your child ... carefully consider the situation, advises an expert. "Take ... respond defensively with ,not my child., Understand that your child ... health services at Saint Joseph,s University in Philadelphia, said in ...
... high body mass index (BMI) between 9 and 12 years of ... blood insulin levels (all risk factors for developing heart disease) by ... bmj.com today. Reassuringly, say the authors, children with ... reach adolescence have better heart disease risk profiles than those who ...
... Mammals began to grow much larger after dinosaurs became extinct ... international team of researchers analyzed the fossils of major groups ... size increased from a maximum of about 10 kilograms (22 ... maximum of 17 tonnes (18.7 U.S. tons) after dinosaurs became ...
... By Amanda Gardner HealthDay Reporter , WEDNESDAY, ... who took a popular class of heartburn drugs while ... heightened risk of birth defects, a large Danish study ... inhibitors (PPIs), include blockbusters such as Prilosec (omeprazole), Prevacid ...
... outbreaks in refugee camps in earthquake-wracked Haiti, a group ... University, and the International Vaccine Institute (IVI) have urged ... cholera vaccines for future humanitarian use. "The ... stockpile of several million doses of cholera vaccine would ...
... Reporter , WEDNESDAY, Nov. 24 (HealthDay News) -- There,s encouraging ... babies. Children whose mothers took certain anti-seizure medications while breast-feeding ... 3, a new study finds. The multi-center study looked ... common antiepileptic drugs, and found no difference in IQ levels ...
Cached Medicine News:Health News:Parents of Bullies Urged to Open Lines of Communication 2Health News:A high BMI in childhood linked to greater heart disease risk in adolescence 2Health News:No Link Between Heartburn Drugs and Birth Defects: Study 2Health News:No Link Between Heartburn Drugs and Birth Defects: Study 3Health News:Experts urge US to create emergency cholera vaccine stockpile for humanitarian use 2Health News:Experts urge US to create emergency cholera vaccine stockpile for humanitarian use 3Health News:Experts urge US to create emergency cholera vaccine stockpile for humanitarian use 4Health News:Women Taking Certain Epilepsy Drugs Can Safely Breast-Feed, Study Suggests 2Health News:Women Taking Certain Epilepsy Drugs Can Safely Breast-Feed, Study Suggests 3
... Guidants 20-year history, the VOYAGER RX Dilatation ... treatment outcomes. It combines a new low ... profile shaft,more flexible markers, and short taper ... and tortuous anatomy with even greater confidence, ...
Test for AFP...
Enzyme Immunoassay for the Quantitative Measurement of Ovarian Cancer Antigen CA-125 in Human Serum...
For the quantitative measurement of human prostatic acid phosphatase (PAP) in human serum....
Medicine Products: